This Week on Life Sciences Digital
On February 26, AI drug discovery specialist Generate Biomedicines priced the largest biotech IPO of 2026 so far — and one of the biggest in nearly three years. The company raised $400 million, selling 25 million shares at $16 each, and is the fifth biotechnology company to go public in February. Including Generate's offering, five biotechs have now banked nearly $1.4 billion in total IPO proceeds this month, making it the most active month for new stock offerings in more than a year. Generate positions itself as an AI-driven drug developer focused on designing protein-based therapeutics, with a lead clinical program in Phase 3 studies for severe asthma, and a platform reach that extends into oncology. The company was backed by Flagship Pioneering, has collected partnerships with both Amgen and Novartis, and has received over $800 million in venture capital since 2018.
Visual summary generated with AI (NotebookLM).
Also This Week:
A landmark piece in Nature this week described a paradigm shift in synthetic biology: researchers are now using computation and genome engineering to intervene in evolution itself, generating new proteins and even whole bacteria from scratch. For the first time, an AI program was used to create an entirely synthetic virus. The article, reviewed across this week's scientific press, frames generative biology as the next chapter after AlphaFold — moving from predicting life's structures to designing entirely new ones.
Rome-based Angelini Pharma has inked a multiyear deal with Massachusetts biotech Quiver Bioscience to advance novel therapies for genetic epilepsies, with Quiver eligible to receive up to $120 million in milestone payments. Quiver's mission is to accelerate neurological therapeutic discoveries by leveraging AI models and its genomic positioning system (GPS) tech, a drug discovery and safety assessment platform. Neurology remains one of AI drug discovery's hardest frontiers — this deal signals European pharma is accelerating its push into the space.
Signals & Market Moves
NVIDIA released its second annual State of AI in Healthcare and Life Sciences survey this week, and the headline number is striking. 70% of respondents now actively deploy AI in their operations, up from 63% in 2024 — a 7-percentage-point jump signaling the technology has crossed from experimental to essential. A full 85% of surveyed executives said AI is helping increase revenue, while 80% reported cost reductions. A notable trend in 2026 is the emergence of agentic AI, with 47% of respondents saying they are actively using or assessing AI agents — including 22% who have already deployed them and 19% planning deployment within the next year. In pharma and biotech specifically, 55% use agentic AI for literature review and nearly half deploy it for drug discovery and biomarker identification.
The Signal: Despite momentum, challenges remain. Smaller organisations report budget constraints and insufficient training data as top barriers, while larger enterprises cite data privacy, security, and regulatory issues. For agentic AI specifically, 40% say compliance with healthcare regulations, including HIPAA, FDA approval processes and GDPR, strongly influences implementation strategies. The ROI has arrived — but the compliance infrastructure to support it at scale is still catching up.Generate Biomedicines wasn't alone this month. All five biotechs that went public in February had lead programs in Phase 2 or Phase 3 testing — a reflection of investor enthusiasm for drugs that have already shown clinical potential, and a departure from the earlier era when platform stories alone could command a listing. The message to AI-native biotechs building pipelines: the capital markets are back, but they want clinical data, not decks.
A quieter but consistent pattern this week: at least 17 licensing deals involving China-discovered drugs — including three more this week — have been struck so far in 2026, surpassing last year's record pace. Dive China's biotech output is now a structural feature of global pharma deal flow, not a trend to watch. For life sciences companies sourcing external innovation, the China channel has become impossible to ignore.
Tool Spotlight from our Life Sciences Digital Database
Competitive landscapes, head-to-head comparisons, trial design benchmarks, and due diligence reports — generated from the most comprehensive clinical evidence database in biotech.
Got a tool for life sciences you’d like more people to know?
Events & Calls
NVIDIA GTC 2026 — San Jose, March 17–21
The flagship AI and technology conference will feature a dedicated life sciences track, with sessions on the BioNeMo platform, AI-native laboratory infrastructure, and the Lilly co-innovation lab. Essential viewing for anyone building AI strategy in pharma, biotech, or CRO.
Impact Challenge: AI for Science
The $30M global open call from Google.org is still accepting applications until April 17, 2026. Selected organizations receive between $500K and $3M, plus six months of pro bono technical support from Google experts and Google Cloud credits. Focus areas include AI for Health & Life Sciences. For research-stage organizations and nonprofits, this is one of the most accessible funding mechanisms in the market right now.
🤝 Want to be featured in a future issue — or explore sponsorship?
We highlight the AI tools, companies, and initiatives shaping the future of life sciences. If you’d like to collaborate, reply to this email or get in touch: [email protected]
